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Editorial Comment 
Inhibition of Platelet Function 
In Vivo or In Vitro by 
Organic Nitrates* 
JOHN D. FOLTS, PHD, FACC 
Madison, Wisconsin 
Organic nitrates have been used to relieve angina since 
Brunton (l) first described their use in 1867. The assumption 
has been that nitrates decrease myocardial oxygen demand 
by reducing preload and afterload. In the last 20 years it has 
been established that unstable angina and possibly silent 
ischemia at rest are often due to platelet aggregates forming 
in stenosed coronary arteries. This platelet thrombus re-
duces coronary flow until the thrombus either disaggregates 
or embolizes distally, thereby restoring coronary flow. Sev-
eral studies (2,3) have clearly demonstrated that aspirin 
reduces myocardial ischemic events in patients with unsta-
ble angina. 
There is considerable interest in being able to measure 
platelet function in vivo and in vitro to determine which 
substances-drugs or hormones-increase or decrease 
platelet activity. Until 1962 the only available means of 
measuring platelet function was clot retraction or bleeding 
time. In 1962 Born (4) developed the platelet aggregometer, 
a device in which light is passed through platelet-rich plasma 
placed in a clear glass cuvette. When a platelet agonist, such 
as collagen or adenosine diphosphate, is injected into the 
platelet-rich plasma, the platelets aggregate, making clumps 
of platelets that then fall to the bottom of the cuvette. As the 
platelets aggregate, the solution clears and the light trans-
mittance increases. The degree to which the platelet-rich 
plasma solution clears is proportional to the functional 
activity of the platelets. Although this technique is useful, it 
takes approximately 90 min from the time blood is drawn 
from a patient or animal until the platelets can be studied. 
Thus, transient changes in platelet activity, such as those 
produced by cigarette smoking, can be missed (5). 
The present study. Stamler and Loscalzo (6) in this issue 
of the Journal carefully review the considerable evidence 
that suggests that part of the antianginal effect of nitro 
compounds given intravenously over time may well be due 
to the antiplatelet effect. The two main methods used to 
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determine the effects of nitrates on platelet function were 
1) in vitro or ex vivo studies using the platelet aggregometer, 
and 2) the established "Folts model of coronary platelet 
thrombosis," as recently reviewed by Bush and Shebuski 
(7). In the past, ex vivo testing of platelets obtained from 
patients receiving nitroglycerin intravenously produced con-
fusing results, in part because of depletion of reduced thiols 
during phlebotomy and preparation of platelet-rich plasma. 
Stamler et al. (8) have clearly shown that replenishing the 
stores of reduced thiols with N-acetylcysteine promotes 
platelet inhibition with intravenous administration of nitro-
glycerin to patients. 
Some confusion also arose using the Folts model of 
coronary thrombosis to study the in vivo effects of organic 
nitrates. This model studies periodic acute platelet thrombus 
formation in stenosed canine coronary arteries with intimal 
damage. The acute platelet thrombus formation followed by 
embolization produces cyclical flow reductions. These cycli-
cal flow reductions will continue for many hours if no 
effective platelet inhibitor is given (7 ,9). In 1981 Kowey et al. 
(10) showed that intracoronary infusions of 80 JLg/min of 
nitroglycerin for 10 min produced a 15 mm Hg fall in arterial 
pressure and significantly decreased the cyclical flow reduc-
tions. In 1982 Folts et al. (11), using this model, observed 
that nitroglycerin given sublingually or topically applied to 
the area of stenosis for 10 or 15 min had no effect on cyclical 
flow reductions even though arterial blood pressure declined 
significantly, indicating that the nitroglycerin was absorbed 
and circulating. In 1990, Golino et al. (12), using the same 
coronary platelet thrombus model, were unable to show 
decreases in cyclical flow reductions with intravenous ad-
ministration of 5 JLglkg per min of nitroglycerin for 30 min. 
They did show that 21 JLg/kg per min of intracoronary 
nitroglycerin given for an unspecified length of time pro-
duced a small decrease in the size and frequency of the 
cyclical flow reductions. However, as Stamler and Loscalzo 
(6) clearly point out in their review in this issue of the 
Journal, the effects of organic nitrates are dose and time 
dependent. Recently it was shown (13) in the Folts model 
that infusions of nitroglycerin, (10 to 15 JLglkg per min for 
1 h) did indeed inhibit in vivo platelet activity and abolished 
acute platelet thrombus formation and the cyclical flow 
reductions. In addition, pretreating the dog with 100 mg/kg 
of N-acetylcysteine, which provides additional reduced thi-
ols, produced abolition of cyclical flow reductions with only 
5 JLg/kg per min of nitroglycerin within 45 min (13). Finally, 
in a pilot study with this model (unpublished observations), 
we found that sodium nitroprusside given intravenously at 
8 to 10 JLg/kg per min abolished acute platelet thrombus 
formation and cyclical flow reductions within only 10 to 
15 min after the onset of infusion. 
Recently Ovize et al. (14) demonstrated in the Folts dog 
model that molsidomine and its metabolite SIN-1 (3 mor-
pholinosydnonimine), a donor of nitric acid, significantly 
reduced acute platelet thrombus formation and cyclical flow 
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reductions. These investigators (14) concluded that the anti-
ischemic properties of SIN-1 may well be due in part to its 
antiplatelet effects. 
Mechanism of platelet activity inhibition. Stamler and 
Loscalzo (6) in their extensive review show that the mech-
anism by which organic nitrates inhibit platelet activity 
appears to be mediated by release of nitric oxide with the 
subsequent elevation of platelet cyclic guanosine monophos-
phate (GMP) and that this can be enhanced by providing 
reduced thiols such as N-acetylcysteine. They also show 
that the effects of organic nitrates on platelets are time 
dependent. Thus, one would not expect to see significant 
platelet inhibition from periodic suplingual application of 
nitrates, and we did not see it when giving nitroglycerin by 
this route in our animal model (11). It remains to be seen 
whether transdermal application of nitrates will have a 
significant platelet-inhibitory effect. 
Potential problems. Two potential problems may occur 
with the use of intravenous nitrates as pharmacologic agents 
to inhibit platelet activity and acute platelet thrombus for-
mation. The first is the potential for producing tolerance, 
which is seen with the hemodynamic effects of nitrates 
clinically (15) and may also occur with the antiplatelet 
effects. The second is the possibility that when blood pres-
sure is decreased by nitrates, there may be an increased 
release of catecholamines that act synergistically with plate-
let-activating factor, collagen and adenosine diphosphate 
(16). It has been shown (17-19) that the platelet inhibitory 
effect of aspirin, for example, is significantly diminished by 
elevated plasma epinephrine and norepinephrine levels. 
These two potenti&l proplems need tp be addressed in 
future studies to delineate the role of organic nitrates as 
platelet inhibitors and to determine if any of the nitrates will 
provide adequate protection when plas!lla catecholamine 
levels are elevated. 
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